Neurologic Dysfunction
11
2
3
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.1%
1 terminated out of 11 trials
66.7%
-19.8% vs benchmark
9%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (11)
ViBandz Feasibility Study
DuraEEG - Duration of EEG and Treatment Outcomes in Critical Care
Optic Nerve Sheath Diameter, Carotid Duplex and Transcranial Duplex as a Prognostic Factor
Identification of Neuroprognostic Factors for Out-of-hospital Cardiopulmonary Arrest (MIRA29)
How Does Pianistic Musical Training Influence the Development of Alzheimer's Disease?
Efficacy of Contrast Enhanced Voiding Urosonography for Urodynamic Studies
Factors Associated With CPC 1-2 in 110 Patients Admitted in French ICU for a Myocardial Infarction Complicated by an OHCA.
Omega 3 and Ischemic Stroke; Fish Oil as an Option
Accessible Mobile Health and Wellness
Development of Potential Biomarkers for Foetal Brain Development After Congenital CMV Infection
NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing